PROLANZA olanzapine 7.5mg tablet blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

olanzapine, Quantity: 7.5 mg

Disponible desde:

Medis Pharma Pty Ltd

Designación común internacional (DCI):

Olanzapine

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: magnesium stearate; microcrystalline cellulose; hyprolose; purified talc; crospovidone; lactose monohydrate; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin

Vía de administración:

Oral

Unidades en paquete:

7, 50, 14, 10, 21, 30, 20, 40, 60, 28

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

For the treatment of schizophrenia and related psychoses. ,Alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. ,For preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.

Resumen del producto:

Visual Identification: White, round, biconvex film coated tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

Estado de Autorización:

Registered

Fecha de autorización:

2011-08-11